G Protein-Coupled Receptors (GPCRs) in advancing GPCR-targeted therapies, including the use of agonists, antagonists, biased ...

Cell membrane proteins hide secret gateways that can be used to modify cell behavior. This has been demonstrated in a study ...

Preclinical Work Advancing with Plans to Select a Next-Generation Oral Small Molecule PTH1R Agonist to Accelerate Toward the Clinic Later This ...

STRASBOURG, France; MONTREAL, Canada; BOSTON, MA, USA I March 20, 2025 I Domain Therapeutics ("Domain" or "the Company"), the GPCR experts harnessing deep ...

Domain leverages its proprietary drug discovery and development approach, founded on a unique platform and unmatched knowledge of GPCR receptor biology, to successfully unlock very challenging ...

The new drug development corporation Daimbio announced on the 25th that it has completed a series A funding round worth 12 ...

Maxion Therapeutics Ltd. has raised $72 million (£58 million) in a series A financing to support its development of antibody-based Knotbody drugs for ion channel- and G protein-coupled receptor (GPCR) ...

By leveraging our world-class GPCR know-how ... an oral small molecule amylin receptor agonist development candidate in investigational new drug (“IND”)-enabling studies, multiple preclinical ...

Maxion Therapeutics Raises $72 million (£58 million) in an Oversubscribed Series A Financing to Advance its KnotBody® ...